National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 22498 [2018-10316]
Download as PDF
<![CDATA[
daltland on DSKBBV9HB2PROD with NOTICES
22498
Federal Register / Vol. 83, No. 94 / Tuesday, May 15, 2018 / Notices
ORI found that Respondent engaged
in research misconduct by knowingly
and intentionally falsifying data
reported in Development 141(12):2414–
28, 2014 Jun (hereafter referred to as
‘‘Development 2014’’).
In addition to making an admission,
Respondent cooperated fully with
ISMMS and ORI and has expressed
remorse for his actions.
Specifically, ORI found that
Respondent:
• used the p-GSK3a/b double bands
in Figure S3B of Development 2014,
removed the lower set of bands,
reordered the remaining bands and used
those bands to represent the actin
control in an experiment comparing the
impact of Tgfb1 and ActB individually
and in combination in primary
oligodendrocyte progenitors (OLPs) and
the oligodendrocyte-derived Oli-Neu
cell line.
• used the densitometry readings
from the falsified actin bands in Figure
S3B of Development 2014 to compare
the density of A+T, Tgfb1, ActB, and
Veh relative to the false actin signal in
Figure S3C–J, creating eight false
graphs.
• falsified the bands representing
Myelin basic protein (Mbp) in Figure 3C
of Development 2014 by cutting and
pasting the bands onto a blank
background and used those false bands
to create a graph showing the density of
Mbp in the presence and absence of
ActB, Tgfb1, and Bmp4.
As a result of this admission,
Respondent has notified Development
that corrections to figures in the paper,
but not to the text, including the
conclusions in Development 2014 are
required.
Dr. John entered into a Voluntary
Settlement Agreement and voluntarily
agreed, beginning on April 26, 2018:
(1) To have his research supervised
for a period of one (1) year; Respondent
agreed that prior to submission of an
application for U.S. Public Health
Service (PHS) support for a research
project on which the Respondent’s
participation is proposed and prior to
Respondent’s participation in any
capacity on PHS-supported research,
Respondent shall ensure that a plan for
supervision of Respondent’s duties is
submitted to ORI for approval; the
supervision plan must be designed to
ensure the scientific integrity of
Respondent’s research contribution;
Respondent agreed that he shall not
participate in any PHS-supported
research until such a supervision plan is
submitted to and approved by ORI;
Respondent agreed to maintain
responsibility for compliance with the
agreed upon supervision plan;
VerDate Sep<11>2014
20:27 May 14, 2018
Jkt 244001
(2) that for one (1) year, any
institution employing him shall submit,
in conjunction with each application for
PHS funds, or report, manuscript, or
abstract involving PHS-supported
research in which Respondent is
involved, a certification to ORI that the
data provided by Respondent are based
on actual experiments or are otherwise
legitimately derived and that the data,
procedures, and methodology are
accurately reported in the application,
report, manuscript, or abstract;
(3) if no supervisory plan is provided
to ORI, to provide certification to ORI at
the conclusion of the supervision period
that he has not engaged in, applied for,
or had his name included on any
application, proposal, or other request
for PHS funds without prior notification
to ORI;
(4) to exclude himself voluntarily
from serving in any advisory capacity to
PHS including, but not limited to,
service on any PHS advisory committee,
board, and/or peer review committee, or
as a consultant for a period of one (1)
year; and
(5) to follow up with the journal
editor regarding his previous request to
correct the following paper to ensure
that the corrections are made:
• Development 141(12):2414–28,
2014 Jun.
Wanda K. Jones,
Interim Director, Office of Research Integrity.
[FR Doc. 2018–10310 Filed 5–14–18; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of Microbiology, Infectious
Diseases and AIDS Initial Review Group
Microbiology and Infectious Diseases
Research Committee.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
Name of Committee: Microbiology,
Infectious Diseases and AIDS Initial Review
Group Microbiology and Infectious Diseases
Research Committee.
Date: June 7–8, 2018.
Time: 9:30 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Frank S. De Silva, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
Room #3E72A, National Institutes of Health/
NIAID, 5601 Fishers Lane, MSC 9834,
Bethesda, MD 20892934, (240) 669–5023,
fdesilva@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: May 10, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–10316 Filed 5–14–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
meeting of the National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel; P41 BTRC Review
(2018/10).
Date: July 5–7, 2018.
Time: 6:00 p.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: Courtyard by Marriott New York
Manhattan/Upper ES, 410 East 92nd Street,
New York, NY 10128.
Contact Person: Manana Sukhareva, Ph.D.,
Scientific Review Officer, National Institute
E:\FR\FM\15MYN1.SGM
15MYN1
]]>Agencies
[Federal Register Volume 83, Number 94 (Tuesday, May 15, 2018)]
[Notices]
[Page 22498]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-10316]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of Microbiology,
Infectious Diseases and AIDS Initial Review Group Microbiology and
Infectious Diseases Research Committee.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Microbiology, Infectious Diseases and AIDS
Initial Review Group Microbiology and Infectious Diseases Research
Committee.
Date: June 7-8, 2018.
Time: 9:30 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 5601 Fishers Lane,
Rockville, MD 20892 (Telephone Conference Call).
Contact Person: Frank S. De Silva, Ph.D., Scientific Review
Officer, Scientific Review Program, Division of Extramural
Activities, Room #3E72A, National Institutes of Health/NIAID, 5601
Fishers Lane, MSC 9834, Bethesda, MD 20892934, (240) 669-5023,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: May 10, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-10316 Filed 5-14-18; 8:45 am]
BILLING CODE 4140-01-P
